NDAINTRAVENOUSPOWDERPriority Review
Approved
Feb 2021
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
4/8 — Partial
Priority Review
NULIBRY (fosdenopterin hydrobromide) by Sentynl Therapeutics is mocs1 gene leading to deficient mocs1a/b dependent synthesis of the intermediate substrate, cpmp. Approved for mortality in patients with molybdenum cofactor deficiency (mocd) type a. First approved in 2021.
Drug data last refreshed 20h ago
Mechanism of Action
MOCS1 gene leading to deficient MOCS1A/B dependent synthesis of the intermediate substrate, cPMP. Substrate replacement therapy with NULIBRY provides an exogenous source of cPMP, which is converted to molybdopterin. Molybdopterin is then converted to molybdenum cofactor, which is needed for the…
Why This Matters for Your Career
Worked on NULIBRY at Sentynl Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.